Cargando…
Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study
Objective To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations. Design Population based cohort study. Participants 493 113 children born in Denmark, 1996-2003. Main outcome measure Major malformations categor...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749925/ https://www.ncbi.nlm.nih.gov/pubmed/19776103 http://dx.doi.org/10.1136/bmj.b3569 |
_version_ | 1782172198553780224 |
---|---|
author | Pedersen, Lars Henning Henriksen, Tine Brink Vestergaard, Mogens Olsen, Jørn Bech, Bodil Hammer |
author_facet | Pedersen, Lars Henning Henriksen, Tine Brink Vestergaard, Mogens Olsen, Jørn Bech, Bodil Hammer |
author_sort | Pedersen, Lars Henning |
collection | PubMed |
description | Objective To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations. Design Population based cohort study. Participants 493 113 children born in Denmark, 1996-2003. Main outcome measure Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005. Results Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low—for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI. Conclusion There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI. |
format | Text |
id | pubmed-2749925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-27499252009-12-02 Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study Pedersen, Lars Henning Henriksen, Tine Brink Vestergaard, Mogens Olsen, Jørn Bech, Bodil Hammer BMJ Research Objective To investigate any association between selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and congenital major malformations. Design Population based cohort study. Participants 493 113 children born in Denmark, 1996-2003. Main outcome measure Major malformations categorised according to Eurocat (European Surveillance of Congenital Anomalies) with additional diagnostic grouping of heart defects. Nationwide registers on medical redemptions (filled prescriptions), delivery, and hospital diagnosis provided information on mothers and newborns. Follow-up data available to December 2005. Results Redemptions for SSRIs were not associated with major malformations overall but were associated with septal heart defects (odds ratio 1.99, 95% confidence interval 1.13 to 3.53). For individual SSRIs, the odds ratio for septal heart defects was 3.25 (1.21 to 8.75) for sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34 (0.33 to 5.41) for fluoxetine. Redemptions for more than one type of SSRI were associated with septal heart defects (4.70, 1.74 to 12.7)). The absolute increase in the prevalence of malformations was low—for example, the prevalence of septal heart defects was 0.5% (2315/493 113) among unexposed children, 0.9% (12/1370) among children whose mothers were prescribed any SSRI, and 2.1% (4/193) among children whose mothers were prescribed more than one type of SSRI. Conclusion There is an increased prevalence of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy, particularly sertraline and citalopram. The largest association was found for children of women who redeemed prescriptions for more than one type of SSRI. BMJ Publishing Group Ltd. 2009-09-23 /pmc/articles/PMC2749925/ /pubmed/19776103 http://dx.doi.org/10.1136/bmj.b3569 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. |
spellingShingle | Research Pedersen, Lars Henning Henriksen, Tine Brink Vestergaard, Mogens Olsen, Jørn Bech, Bodil Hammer Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title | Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title_full | Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title_fullStr | Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title_full_unstemmed | Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title_short | Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
title_sort | selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2749925/ https://www.ncbi.nlm.nih.gov/pubmed/19776103 http://dx.doi.org/10.1136/bmj.b3569 |
work_keys_str_mv | AT pedersenlarshenning selectiveserotoninreuptakeinhibitorsinpregnancyandcongenitalmalformationspopulationbasedcohortstudy AT henriksentinebrink selectiveserotoninreuptakeinhibitorsinpregnancyandcongenitalmalformationspopulationbasedcohortstudy AT vestergaardmogens selectiveserotoninreuptakeinhibitorsinpregnancyandcongenitalmalformationspopulationbasedcohortstudy AT olsenjørn selectiveserotoninreuptakeinhibitorsinpregnancyandcongenitalmalformationspopulationbasedcohortstudy AT bechbodilhammer selectiveserotoninreuptakeinhibitorsinpregnancyandcongenitalmalformationspopulationbasedcohortstudy |